Printer Friendly

Semma Therapeutics Raises $114M In Series B Financing.

CAMBRIDGE, Mass., November 30, 2017 -- Semma Therapeutics announced t had raised $114 million in Series B financing.

The funds will be used to bring Semma's lead development program, encapsulated stem cell-derived islets, through clinical proof-of-concept in patients and to continue exploration of other regenerative medicine therapeutics.

The company's proprietary technologies enable the generation of billions of functional, insulin-producing beta cells which have the potential to control blood sugar in people living with diabetes.

Eight Roads Ventures and Cowen Healthcare Investments co-led the financing with significant investments from all existing investors including MPM Capital, F-Prime Capital Partners and ARCH Venture Partners, existing strategic partners Novartis, Medtronic and the JDRF T1D Fund, and new investors including ORI Healthcare Fund, Wu Capital, 6 Dimensions Capital and SinoPharm Capital.

Semma Therapeutics is a stem cell company based on the research conducted by Harvard University's Douglas Melton. He discovered a way to generate billions of functional, insulin-producing beta cells in the laboratory from stem cells.

Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art device to provide a functional cure for patients with diabetes.


COPYRIGHT 2017 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Finance & Funding
Publication:Stem Cell Business News
Date:Dec 11, 2017
Previous Article:Second Cellular Processing Patent.
Next Article:Working Together To Develop iPSC-Derived Cancer Immunotherapies.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |